What is the 13F Pro Quality Score for CUE?

13F Pro ranks Cue Biopharma, Inc. (CUE) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CUE's current score at https://13fpro.ai/research/CUE (free sign-up required for the full ranking).

Where does 13F Pro source CUE data?

All Cue Biopharma, Inc. fundamentals and ownership data come directly from SEC EDGAR. Cue Biopharma, Inc. files with the SEC under CIK 1645460. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CUE in?

Cue Biopharma, Inc. (CUE) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CUE research updated on 13F Pro?

CUE's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Cue Biopharma, Inc.(CUE)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1645460 CUE stock profile & AI dashboard →

13F Pro Quality Score

23.2/100

Rank #2,621 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

91.1/100

Profitability

4.5/100

Balance Sheet

1.4/100

Earnings Quality

30.0/100

Free Cash Flow

4.5/100

Institutional Flow

10.8/100

Revenue Scale

3.8/100

Dilution Risk

10.8/100

CUE Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Cue Biopharma, Inc. (CUE), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CUE at 23.2/100 on a 32-signal composite quality model, placing it at rank #2,621 of 2,879 stocks — the bottom half of the AI-ranked universe. CUE scores in the top quartile across revenue growth (91.1). Areas of concern include balance sheet strength (1.4) and revenue scale (3.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 10.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Cue Biopharma, Inc. reports quarterly revenue of $5.7M, net income of $-5.2M, an operating margin of -94.1%. Top institutional holders of CUE by reported 13-F value include Bleichroeder, GC Wealth Management RIA,, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. CUE trades on the Nasdaq exchange and files with the SEC under CIK 1645460. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CUE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cue Biopharma, Inc. directly from SEC EDGAR. Cue Biopharma, Inc.'s 13F Pro composite quality score has ranged between 23 and 26 since 2026, currently 23.2 — a stable long-term trajectory across 8 quarterly and live scoring snapshots.

Revenue

Q1 2026

$5.7M

Net Income

Q1 2026

$-5.2M

Free Cash Flow

Q1 2026

$-11.1M

Operating Margin

Q1 2026

-94.1%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+195.7% YoY

$27.5MFY 2025

FY21 $14.9MFY22 $1.2MFY24 $9.3MFY25 $27.5M

Net Income

+34.6% YoY

$-26.6MFY 2025

FY21 $-44.2MFY22 $-53.0MFY24 $-40.7MFY25 $-26.6M

Operating Income

+36.0% YoY

$-26.6MFY 2025

FY21 $-43.7MFY22 $-53.2MFY24 $-41.5MFY25 $-26.6M

EPS (Diluted)

+61.1% YoY

$-0.28FY 2025

FY21 $-1.41FY22 $-1.49FY24 $-0.72FY25 $-0.28

Total Assets

+31.1% YoY

$42.2MFY 2025

FY21 $83.4MFY22 $91.3MFY24 $32.2MFY25 $42.2M

Total Debt

—FY 2025

FY21 $0.00FY22 $10.1MFY24 $37.0KFY25 —

Op. Cash Flow

+40.3% YoY

$-21.7MFY 2025

FY21 $-38.8MFY22 $-41.8MFY24 $-36.3MFY25 $-21.7M

Metric	FY 2025	FY 2024	FY 2022	FY 2021	FY 2020	FY 2017
Revenue	$27.5M +195.7%	$9.3M +645.9%	$1.2M -91.7%	$14.9M +373.7%	$3.2M	—
Net Income	$-26.6M +34.6%	$-40.7M +23.3%	$-53.0M -20.0%	$-44.2M +1.4%	$-44.8M -92.8%	$-23.2M
Operating Income	$-26.6M +36.0%	$-41.5M +22.0%	$-53.2M -21.8%	$-43.7M +3.0%	$-45.0M -93.9%	$-23.2M
EPS (Diluted)	$-0.28 +61.1%	$-0.72 +51.7%	$-1.49 -5.7%	$-1.41	—	—
Total Assets	$42.2M +31.1%	$32.2M -64.7%	$91.3M +9.5%	$83.4M -16.2%	$99.5M +48.7%	$67.0M
Total Debt	—	$37.0K -99.6%	$10.1M	$0.00	—	—
Operating Cash Flow	$-21.7M +40.3%	$-36.3M +13.1%	$-41.8M -7.6%	$-38.8M -19.5%	$-32.5M -167.6%	$-12.1M

AI Insight: CUE Financial Trends

Q4 2025 inflection to profitability reversed sharply in Q1 2026, with revenue collapsing 73% and operating cash flow deteriorating.

• Q4 2025 revenue spiked to $22M (from $2M in Q3 2025) and delivered $2M net income, first profitable quarter in dataset.

• Q1 2026 revenue fell 73% to $6M; net loss widened to $5M and operating cash flow deteriorated to $-11M.

• Total debt cleared to $0M by Q4 2024, but equity volatility remains pronounced (ranged $7M–$26M across period).

⚠ Q4 2025 profitability appears unsustainable—single quarter spike or one-time event? Q1 2026 reversion critical signal.

⚠ Operating cash flow has been negative in 6 of 8 quarters; Q1 2026 at $-11M represents worst performance.

⚠ Revenue highly volatile (range $0M–$22M); no clear growth trajectory or recurring revenue base evident.

AI Insight: CUE Ratio Trends

Cue Biopharma swung from Q4 2025 profitability (OpMargin +9.0%, ROIC +29.9%) to severe Q1 2026 losses across all metrics.

• Operating margin collapsed from +9.0% in Q4 2025 to -94.1% in Q1 2026; net profit margin fell from +7.2% to -91.1%.

• ROIC plummeted from +29.9% in Q4 2025 to -99.1% in Q1 2026; ROA declined from +15.0% to -67.1%.

• Debt-to-equity remained minimal or absent across most recent quarters (0.00 to 0.29), indicating low leverage.

⚠ Q1 2026 represents a dramatic reversal from Q4 2025's sole profitable quarter—investigate underlying operational or accounting drivers.

⚠ Persistent negative profitability metrics (TTM OpMargin -59.9%, NPM -59.7%) despite Q4 2025 blip suggest structural cash burn.

Get alerted when CUE's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Cue Biopharma, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CUE

Bleichroeder LP
$1.6M6,819,164 sh
GC Wealth Management RIA, LLC
$1.1M4,631,644 sh
VANGUARD CAPITAL MANAGEMENT LLC
$565.2K2,457,452 sh
Lion Point Capital, LP
$506.4K2,202,854 sh
GEODE CAPITAL MANAGEMENT, LLC
$244.8K1,064,690 sh
VANGUARD FIDUCIARY TRUST CO
$125.0K543,585 sh
Robertson Stephens Wealth Management, LLC
$110.0K478,500 sh
BlackRock, Inc.
$103.3K449,161 sh
Texas Capital Bank Wealth Management Services Inc
$91.4K397,421 sh
ANGELES WEALTH MANAGEMENT, LLC
$71.3K310,000 sh

Fund	Value	Shares
Bleichroeder LP	$1.6M	6,819,164
GC Wealth Management RIA, LLC	$1.1M	4,631,644
VANGUARD CAPITAL MANAGEMENT LLC	$565.2K	2,457,452
Lion Point Capital, LP	$506.4K	2,202,854
GEODE CAPITAL MANAGEMENT, LLC	$244.8K	1,064,690
VANGUARD FIDUCIARY TRUST CO	$125.0K	543,585
Robertson Stephens Wealth Management, LLC	$110.0K	478,500
BlackRock, Inc.	$103.3K	449,161
Texas Capital Bank Wealth Management Services Inc	$91.4K	397,421
ANGELES WEALTH MANAGEMENT, LLC	$71.3K	310,000

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CUE on your watchlist

Track score changes the day Cue Biopharma, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CUE a good stock to buy?

13F Pro's AI-powered analysis of Cue Biopharma, Inc. (CUE) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CUE are available on the CUE stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own CUE?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CUE. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Cue Biopharma, Inc.'s investment landscape.